Omega-3 polyunsaturated fatty acids in cardiology

Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesi...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	N. V. Perova [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2005

Schlagwörter:	омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор

Übergeordnetes Werk:	In: Кардиоваскулярная терапия и профилактика - «SILICEA-POLIGRAF» LLC, 2019, 4(2005), 4, Seite 101-107
Übergeordnetes Werk:	volume:4 ; year:2005 ; number:4 ; pages:101-107

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ030941857

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ030941857
003	DE-627
005	20230410104804.0
007	cr uuu---uuuuu
008	230226s2005 xx \|\|\|\|\|o 00\| \|\|rus c
035			\|a (DE-627)DOAJ030941857
035			\|a (DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC666-701
100	0		\|a N. V. Perova \|e verfasserin \|4 aut
245	1	0	\|a Omega-3 polyunsaturated fatty acids in cardiology
264		1	\|c 2005
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment.
650		4	\|a омега-3 полиненасыщенные жирные кислоты
650		4	\|a эйкозапентаеновая кислота
650		4	\|a докозагексаеновая кислота
650		4	\|a омакор
653		0	\|a Diseases of the circulatory (Cardiovascular) system
773	0	8	\|i In \|t Кардиоваскулярная терапия и профилактика \|d «SILICEA-POLIGRAF» LLC, 2019 \|g 4(2005), 4, Seite 101-107 \|w (DE-627)1725534363 \|x 26190125 \|7 nnns
773	1	8	\|g volume:4 \|g year:2005 \|g number:4 \|g pages:101-107
856	4	0	\|u https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23 \|z kostenfrei
856	4	0	\|u https://cardiovascular.elpub.ru/jour/article/view/994 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1728-8800 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2619-0125 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2005 \|e 4 \|h 101-107

Indexfelder

author_variant	n v p nvp
matchkey_str	article:26190125:2005----::mg3oynauaeftycd
hierarchy_sort_str	2005
callnumber-subject-code	RC
publishDate	2005
allfields	(DE-627)DOAJ030941857 (DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23 DE-627 ger DE-627 rakwb rus RC666-701 N. V. Perova verfasserin aut Omega-3 polyunsaturated fatty acids in cardiology 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment. омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 4, Seite 101-107 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:4 pages:101-107 https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/994 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 4 101-107
spelling	(DE-627)DOAJ030941857 (DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23 DE-627 ger DE-627 rakwb rus RC666-701 N. V. Perova verfasserin aut Omega-3 polyunsaturated fatty acids in cardiology 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment. омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 4, Seite 101-107 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:4 pages:101-107 https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/994 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 4 101-107
allfields_unstemmed	(DE-627)DOAJ030941857 (DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23 DE-627 ger DE-627 rakwb rus RC666-701 N. V. Perova verfasserin aut Omega-3 polyunsaturated fatty acids in cardiology 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment. омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 4, Seite 101-107 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:4 pages:101-107 https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/994 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 4 101-107
allfieldsGer	(DE-627)DOAJ030941857 (DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23 DE-627 ger DE-627 rakwb rus RC666-701 N. V. Perova verfasserin aut Omega-3 polyunsaturated fatty acids in cardiology 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment. омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 4, Seite 101-107 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:4 pages:101-107 https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/994 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 4 101-107
allfieldsSound	(DE-627)DOAJ030941857 (DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23 DE-627 ger DE-627 rakwb rus RC666-701 N. V. Perova verfasserin aut Omega-3 polyunsaturated fatty acids in cardiology 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment. омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 4, Seite 101-107 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:4 pages:101-107 https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/994 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 4 101-107
language	Russian
source	In Кардиоваскулярная терапия и профилактика 4(2005), 4, Seite 101-107 volume:4 year:2005 number:4 pages:101-107
sourceStr	In Кардиоваскулярная терапия и профилактика 4(2005), 4, Seite 101-107 volume:4 year:2005 number:4 pages:101-107
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Кардиоваскулярная терапия и профилактика
authorswithroles_txt_mv	N. V. Perova @@aut@@
publishDateDaySort_date	2005-01-01T00:00:00Z
hierarchy_top_id	1725534363
id	DOAJ030941857
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030941857</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2005 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030941857</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. V. Perova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Omega-3 polyunsaturated fatty acids in cardiology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">омега-3 полиненасыщенные жирные кислоты</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">эйкозапентаеновая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">докозагексаеновая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">омакор</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">4(2005), 4, Seite 101-107</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:101-107</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/994</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2005</subfield><subfield code="e">4</subfield><subfield code="h">101-107</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	N. V. Perova
spellingShingle	N. V. Perova misc RC666-701 misc омега-3 полиненасыщенные жирные кислоты misc эйкозапентаеновая кислота misc докозагексаеновая кислота misc омакор misc Diseases of the circulatory (Cardiovascular) system Omega-3 polyunsaturated fatty acids in cardiology
authorStr	N. V. Perova
ppnlink_with_tag_str_mv	@@773@@(DE-627)1725534363
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	26190125
topic_title	RC666-701 Omega-3 polyunsaturated fatty acids in cardiology омега-3 полиненасыщенные жирные кислоты эйкозапентаеновая кислота докозагексаеновая кислота омакор
topic	misc RC666-701 misc омега-3 полиненасыщенные жирные кислоты misc эйкозапентаеновая кислота misc докозагексаеновая кислота misc омакор misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc омега-3 полиненасыщенные жирные кислоты misc эйкозапентаеновая кислота misc докозагексаеновая кислота misc омакор misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc омега-3 полиненасыщенные жирные кислоты misc эйкозапентаеновая кислота misc докозагексаеновая кислота misc омакор misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Кардиоваскулярная терапия и профилактика
hierarchy_parent_id	1725534363
hierarchy_top_title	Кардиоваскулярная терапия и профилактика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1725534363
title	Omega-3 polyunsaturated fatty acids in cardiology
ctrlnum	(DE-627)DOAJ030941857 (DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23
title_full	Omega-3 polyunsaturated fatty acids in cardiology
author_sort	N. V. Perova
journal	Кардиоваскулярная терапия и профилактика
journalStr	Кардиоваскулярная терапия и профилактика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2005
contenttype_str_mv	txt
container_start_page	101
author_browse	N. V. Perova
container_volume	4
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	N. V. Perova
title_sort	omega-3 polyunsaturated fatty acids in cardiology
callnumber	RC666-701
title_auth	Omega-3 polyunsaturated fatty acids in cardiology
abstract	Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment.
abstractGer	Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment.
abstract_unstemmed	Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	4
title_short	Omega-3 polyunsaturated fatty acids in cardiology
url	https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23 https://cardiovascular.elpub.ru/jour/article/view/994 https://doaj.org/toc/1728-8800 https://doaj.org/toc/2619-0125
remote_bool	true
ppnlink	1725534363
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC666-701
up_date	2024-07-03T17:51:00.517Z
_version_	1803581192166965248
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030941857</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2005 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030941857</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ05ce025dee2d484abf6307bfc4dcae23</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. V. Perova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Omega-3 polyunsaturated fatty acids in cardiology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - have some important biological effects that can be used in cardiology. Long-chain omega-3 PUFA intake, in the dose of 3-4 g/d and more, decrease hypertriglyceridemia, thrombogenesis, inflammatory and immune processes, and vascular tonus. Free EPA and DHA act as structural components of cell membranes; they modify –inhibit trans-membrane ion channels; demonstrate antiarrhythmic effects; increase heart rate variability. In GISSI-Prevenzione study, among patients taking omega-3 PUFA, the incidence of combined end-point (total mortality, nonfatal myocardial infarction (MI), and stroke (S)) was lower than that in placebo group, by 15-16% (Р=0.02). Cardiovascular death risk, plus nonfatal MI and S risk, was also lower, comparing to placebo group (-20-21%; Р=0.006). The risk reduction was maximal (-45%; Р=0.0006) for sudden death; its risk was decreased as early as after 4 months of treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">омега-3 полиненасыщенные жирные кислоты</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">эйкозапентаеновая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">докозагексаеновая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">омакор</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">4(2005), 4, Seite 101-107</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:101-107</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/05ce025dee2d484abf6307bfc4dcae23</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/994</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2005</subfield><subfield code="e">4</subfield><subfield code="h">101-107</subfield></datafield></record></collection>
score	7.402128

Nicht das Richtige dabei?

Schreiben Sie uns!

Omega-3 polyunsaturated fatty acids in cardiology

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?